Thermo Fisher Scientific Inc. (NYSE:TMO) Receives $616.10 Consensus Price Target from Brokerages

Thermo Fisher Scientific Inc. (NYSE:TMO) has been assigned an average rating of “Moderate Buy” from the twenty-three research firms that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $616.10.

Several brokerages have weighed in on TMO. Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Morgan Stanley reiterated an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Barclays lowered their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Finally, Citigroup lifted their target price on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research note on Friday, January 30th.

Insider Buying and Selling

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is owned by insiders.

Institutional Trading of Thermo Fisher Scientific

A number of institutional investors have recently modified their holdings of the business. Western Wealth Management LLC boosted its position in Thermo Fisher Scientific by 31.7% during the first quarter. Western Wealth Management LLC now owns 5,918 shares of the medical research company’s stock worth $2,909,000 after purchasing an additional 1,424 shares in the last quarter. McIlrath & Eck LLC boosted its position in Thermo Fisher Scientific by 18.9% during the first quarter. McIlrath & Eck LLC now owns 353 shares of the medical research company’s stock worth $174,000 after purchasing an additional 56 shares in the last quarter. Paragon Private Wealth Management LLC boosted its position in Thermo Fisher Scientific by 3.5% during the first quarter. Paragon Private Wealth Management LLC now owns 759 shares of the medical research company’s stock worth $373,000 after purchasing an additional 26 shares in the last quarter. Kentucky Retirement Systems raised its holdings in shares of Thermo Fisher Scientific by 25.8% in the first quarter. Kentucky Retirement Systems now owns 29,835 shares of the medical research company’s stock worth $14,665,000 after acquiring an additional 6,125 shares during the last quarter. Finally, Tri Locum Partners LP acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth $65,085,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 1.4%

TMO opened at $448.34 on Friday. The firm has a market cap of $166.61 billion, a price-to-earnings ratio of 24.65, a price-to-earnings-growth ratio of 1.96 and a beta of 0.88. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $643.99. The business’s 50 day moving average is $483.39 and its two-hundred day moving average is $540.37. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts predict that Thermo Fisher Scientific will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.